Results 101 to 110 of about 1,443,667 (357)

Emerging new therapeutic antibody derivatives for cancer treatment

Signal Transduction and Targeted Therapy, 2022
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin, Yanping Sun, Xiao Liang, Xinyu Gu, Jiangtao Ning, Yingchun Xu, Shuqing Chen, Liqiang Pan   +7 more
doaj   +1 more source

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia

Advanced Science, EarlyView.
A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang, Ruizhi Lai, Xinpei Wang, Xu Chen, Youjian Zhou, Shengbin Li, Xiaohui Qiu, Zekai Zeng, Jianye Yuan, Jinghuan Mao, Zhidong Chen, Junqing Wang   +11 more
wiley   +1 more source

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

Antibodies, 2018
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds.
Pallavi Bhatta, David P. Humphreys
doaj   +1 more source

Producing and prospects for the use of bispecific antibodies for the treatment of cancer

Успехи молекулярной онкологии, 2019
Bispecific antibody molecules contain two different antigen-binding centers. Particular interest in bispecific antibodies is due to their therapeutic application.
S. E. Sedykh, G. A. Nevinsky
doaj   +1 more source

Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies

OncoTargets and Therapy
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described.
Wen, Xiaoli, Xu, Gaosi
openaire   +2 more sources

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Harnessing MerTK agonism for targeted therapeutics

mAbs, 2020
Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies.
Vivekananda Kedage, Diego Ellerman, Yongmei Chen, Wei-Ching Liang, Joven Borneo, Yan Wu, Minhong Yan   +6 more
doaj   +1 more source

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Clinical Cancer Research, 2020
Purpose: With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer.
M. Lakins, A. Koers, R. Giambalvo, J. Munoz-Olaya, R. Hughes, E. Goodman, S. Marshall, F. Wollerton, Sarah Batey, D. Gliddon, M. Tuna, N. Brewis   +11 more
semanticscholar   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

American Journal of Hematology, EarlyView.
ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamara   +13 more
wiley   +1 more source

Effect of antibody levels on the spread of disease in multiple infections [PDF]

There are complex interactions between antibody levels and epidemic propagation, the antibody level of an individual influences the probability of infection, and the spread of the virus influences the antibody level of each individual. There exist some viruses that, in their natural state, cause antibody levels in an infected individual to gradually ...
arxiv   +1 more source